🏭 Over 200 employees from the site will join Thermo Fisher after the purchase, expected to finalize in late 2025. This move strengthens their partnership and manufacturing capabilities. 🧪
Introduction:
This article discusses Thermo Fisher Scientific’s recent agreement to acquire Sanofi’s sterilized manufacturing site in Ridgefield, New Jersey. This acquisition represents a strategic expansion of Thermo Fisher’s manufacturing capabilities in the pharmaceutical sector, underpinning its commitment to meet the growing demands of biotech and pharma clients for essential medicines.
- Thermo Fisher Scientific has signed an agreement to acquire Sanofi’s sterile manufacturing site in Ridgefield, NJ, continuing the production of therapies for Sanofi.
- The Ridgefield facility specializes in sterile fill-finish and packaging and employs over 200 workers who will transition to Thermo Fisher.
- Marc N. Casper, CEO of Thermo Fisher, emphasized the acquisition’s potential to enhance U.S. manufacturing capabilities and support pharmaceutical customers with critical production capacity.
- Brendan O’Callaghan from Sanofi highlighted the acquisition as an opportunity to strengthen their long-term partnership and ensure a continuous supply of high-quality products.
- The acquisition is projected to complete in the second half of 2025, at which point the Ridgefield facility will join Thermo Fisher’s pharma services business.
Conclusion:
The acquisition of Sanofi’s Ridgefield site by Thermo Fisher highlights a significant movement within the pharmaceutical manufacturing industry, enhancing capabilities and collaboration for future growth. This strategic partnership not only secures the production of key medicines but also positions Thermo Fisher to better serve the increasing demands of the pharmaceutical and biotech sectors in the U.S.
